Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.48 |
| ▸ | HTR2A | P28223 | 10/20 | 0.48 |
| ▸ | HTR2B | P41595 | 10/20 | 0.48 |
| ▸ | KHK | P50053 | 3/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16423522 | 0.82 | KHK (0.44) | HTR2CHTR2AHTR2BKHKIRAK4 | |
| SCHEMBL950746 | 0.80 | EIF2AK4 (0.40) | HTR2CHTR2AHTR2BKHKIDH1 | |
| SCHEMBL18704846 | 0.80 | HTR2A (0.35) | HTR2CHTR2AHTR2BIDH1EIF2AK4 | |
| SCHEMBL28821988 | 0.79 | IRAK4 (0.41) | HTR2CHTR2AHTR2BIRAK4IDH1 | |
| SCHEMBL22989672 | 0.79 | EIF2AK4 (0.35) | HTR2CHTR2AHTR2BKHKIDH1 | |
| SCHEMBL21503406 | 0.79 | PRMT6 (0.34) | HTR2CHTR2AHTR2BIDH1EIF2AK4 | |
| SCHEMBL21503651 | 0.79 | PRMT6 (0.34) | HTR2CHTR2AHTR2BIDH1EIF2AK4 | |
| SCHEMBL31390069 | 0.79 | HTR2A (0.34) | HTR2CHTR2AHTR2BIDH1EIF2AK4 | |
| SCHEMBL14636724 | 0.78 | SLC6A2 (0.35) | HTR2CHTR2AHTR2BKHKIDH1 | |
| Hydrochloric Acid SCHEMBL21492706 | 0.77 | PRMT6 (0.33) | HTR2CHTR2AHTR2BIDH1EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| EP-1786806-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | HTR2C 3095/4885HTR2A 2229/4885HTR2B 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.